ArticleDiscover oncology2025
Development and validation of a leukemia prognostic model through single-cell RNA sequencing and machine learning approaches.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deep learning based individualized cross-platform molecular subtype classification of B-lineage acute lymphoblastic leukemia.NPJ precision oncology · 2026Article
- Recent advances in deep learning for leukemia diagnosis: a scoping review of diagnostic modalities and fusion-based approaches.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLeukemia prognosis varies significantly among patients, highlighting the need for accurate prediction tools. Emerging evidence suggests that the immune microenvironment plays a crucial role in leukemia progression and treatment response.
methodsWe analyzed RNA expression profiles and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, supplemented by single-cell RNA sequencing datasets. Differential gene expression analysis was performed using stringent criteria (logFC > 1, FDR < 0.05) to identify leukemia-associated genes. Ten distinct machine learning algorithms, including Lasso, CoxBoost, and ensemble methods, were implemented for prognostic model development with cross-platform validation. Single-cell analysis employed Seurat for quality control and cell type annotation, while CellChat algorithm mapped intercellular communication networks. Experimental validation was conducted using quantitative RT-PCR analysis of key immune markers (TLR2, TLR4, CCR7, IL18) in U937 and K562 leukemia cell lines compared to normal peripheral blood mononuclear cells.
resultsThe machine learning-derived prognostic model demonstrated exceptional predictive performance with area under the curve values of 0.874, 0.891, and 0.925 for 1-, 2-, and 3-year survival endpoints, respectively. Six critical immune regulatory genes (TLR2, TLR4, CCR7, IL18, TIRAP, FOXP3) were identified as both differentially expressed and prognostically significant, with IL18 showing the highest discriminative capacity (AUC = 0.983). RT-PCR validation confirmed significant upregulation of all tested genes in leukemia cell lines: TLR2 (3.8-fold in U937, 2.2-fold in K562), TLR4 (3.4-fold in U937, 1.8-fold in K562), CCR7 (4.1-fold in U937, 2.7-fold in K562), and IL18 (5.2-fold in U937, 3.6-fold in K562) compared to normal controls (all p < 0.05). Single-cell analysis revealed substantial cellular heterogeneity with cell type-specific expression patterns and complex intercellular communication networks involving B cells, T cells, natural killer cells, and dendritic cells.
conclusionThis study provides a reliable prognostic tool for leukemia and offers insights into the critical role of the immune microenvironment in leukemia pathogenesis. Our findings may guide the development of personalized immunotherapy strategies for leukemia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.